



## Online solid phase extraction with liquid chromatography–tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples

Jasper Stevens<sup>a</sup>, Dirk-Jan van den Berg<sup>a</sup>, Sanne de Ridder<sup>a</sup>, Harm A.G. Niederländer<sup>a</sup>, Piet Hein van der Graaf<sup>b</sup>, Meindert Danhof<sup>a</sup>, Elizabeth C.M. de Lange<sup>a,\*</sup>

<sup>a</sup> Division of Pharmacology, LACDR Leiden University, Leiden, The Netherlands

<sup>b</sup> Pfizer Global Research and Development, Sandwich, Kent, England, United Kingdom

### ARTICLE INFO

#### Article history:

Received 30 October 2009

Accepted 19 February 2010

Available online 26 February 2010

#### Keywords:

Pharmacokinetics

Intranasal administration

Microdialysis

Rat

Remoxipride

Raclopride

### ABSTRACT

Remoxipride is a selective dopamine D<sub>2</sub> receptor antagonist, and useful as a model compound in mechanism-based pharmacological investigations. To that end, studies in small animals with serial sampling over time are needed. For these small volume samples currently no suitable analytical methods are available. We propose analytical methods for the detection of low concentrations remoxipride in small sample volumes of plasma, brain homogenate, and brain microdialysate, using online solid phase extraction with liquid chromatography–tandem mass spectrometry. Method development, optimization and validation are described in terms of calibration curves, extraction yield, lower limit of quantification (LLOQ), precision, accuracy, inter-day- and intra-day variability. The 20 µl plasma samples showed an extraction yield of 76%, with a LLOQ of 0.5 ng/ml. For 0.6 ml brain homogenate samples the extraction yield was 45%, with a LLOQ of 1.8 ng/ml. The 20 µl brain microdialysate samples, without pre-treatment, had a LLOQ of 0.25 ng/ml. The precision and accuracy were well within the acceptable 15% range. Considering the small sample volumes, the high sensitivity and good reproducibility, the analytical methods are suitable for analyzing small sample volumes with low remoxipride concentrations.

© 2010 Elsevier B.V. All rights reserved.

### 1. Introduction

Mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modeling of dopaminergic agents following different routes of administration of in preclinical studies *in vivo* is anticipated to provide key knowledge to predict efficacious doses and the time-course of dopaminergic drug effects in man. Remoxipride is a substituted benzamide and is a weak, but very selective, dopamine D<sub>2</sub> receptor antagonist. It was originally intended to be used as an atypical antipsychotic (Roxiam<sup>®</sup>) but taken from the market in 1993. Remoxipride is, however, very useful as a model compound in mechanism-based PK–PD studies on the dopaminergic system in small animals.

With our ultimate aim being to build a mechanism-based PK–PD model of remoxipride, we first need to characterize the pharmacokinetic part of the model, i.e. determining the transport of remoxipride across the blood–brain barrier [1] and consecutive

distribution between extracellular and intracellular space. Especially the free drug concentrations in the brain extracellular fluid surrounding the membrane receptors, as can be measured with intracerebral microdialysis, are of interest as membrane receptors are important targets for many drugs including remoxipride [2]. Plasma pharmacokinetics can be derived from serial plasma samples, brain extracellular fluid pharmacokinetics can be determined from collecting brain microdialysates, and total brain concentrations can be obtained from the brain, obtained from each animal at the end of the experiment.

As summarized in Table 1, in 1987, De Ruyter et al. [3] described an analytical method for remoxipride in plasma using reversed-phase (RP) liquid chromatography (LC) with direct injection of 1 ml untreated plasma diluted with 10 mM phosphate buffer (1:1, v/v) into a disposable precolumn (C-18) treated with hexadecyltrimethylammonium bromide. A post-column ion-pair extraction with 9,10-demethoxy-anthracene-2-sulphonate allowed detection with a fluorescence detector. In 1990 Nilsson [4] described a more simple and robust analytical method using a two-step liquid–liquid extraction, with higher sensitivity. This was followed by the method of Chiou and Lo [5] who, in 1992, described a faster way of measuring remoxipride concentrations, using an easier extraction step, RP high-pressure liquid chromatog-

\* Corresponding author at: LACDR/Pharmacology, Leiden University, Gorlaeus Laboratories, Einsteinweg 55, 2333 CC Leiden, The Netherlands.  
Tel.: +31 71 527 6330; fax: +31 71 527 6292.

E-mail address: [l.lange@lacdr.leidenuniv.nl](mailto:l.lange@lacdr.leidenuniv.nl) (E.C.M. de Lange).

**Table 1**  
Overview of analytical methods to determine remoxipride concentrations in plasma.

	de Ruyter [3]	Nilsson [4,7,8]	Chiou [5]	DePuy [6]
Sample volume plasma (ml)	>0.5	1	2 <sup>a</sup>	0.5
Sample preparation	PCE	LLE	LLE	LLE + P
Internal standard	–	3B	–	3B
Injection volume (ml)	1	0.2	0.05	0.1
Flow rate (ml/min)	1	1.3	1.3	0.58–0.70
Chromatography	RP LC	RP LC	RF HPLC	HP LC
Detection	FL	FL	UV	UV
Run time (min)	8	–	6	>40.6
Retention time (min)	–	–	2.8	22.6
Extraction yield (%)	88 ± 4	85 <sup>a</sup>	75	88.1 ± 10.2 <sup>b</sup>
LLOD (ng/ml)	1	–	–	0.01
LLOQ (ng/ml)	–	0.742	12.5	20
Intra-day (%)	3.5	5.2	0.6–9.7	7
Inter-day (%)	3.5	2.3	1.1–4.4	4.5

RP, reverse phase; LC, liquid chromatography; HP, high pressure; LLOD, lower limit of detection ( $3 \times$  noise ratio); LLOQ, lower limit of quantification; PCE, post-column extraction; LLE, liquid–liquid extraction; p, prefilter; 3B, 3-bromo-N-[(1-propyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenzamide; –, unknown.

<sup>a</sup> For low concentration range only.

<sup>b</sup> Extraction recovery only.

raphy (HPLC) with ultraviolet detection (UV). In 1997, DePuy et al. [6] described an analysis using a chiral OD-R column, HPLC, and UV detection, allowing the separate measurement of the remoxipride enantiomers. In the research, evidence was provided that *in vivo* conversion of the R- to S-enantiomer does not occur, and confirmed stability in repetitive freeze–thaw cycles. Pharmacological investigations comprise full understanding of the distribution of drug throughout the body, including the determination of free drug concentrations in brain. Therefore, Main et al. [7] measured remoxipride in cerebral spinal fluid using the method described by Nilsson [4].

The earlier published analytical methods presented above [3–8] require rather large plasma or cerebral spinal fluid samples ranging from 0.5 to 2 ml, which can be obtained from humans in clinical studies (Table 1). In preclinical PK–PD studies, however, small laboratory animals are mostly used, thereby limiting the sample size. Based on Dutch legislation, quality of research, and animal ethics, the maximal obtainable blood volume in rats is 8 ml/kg/day [9]. Together with the strong need for sampling over time in pharmacokinetic studies, 9–10 blood samples of 200  $\mu$ l can be taken per day, resulting in approximately 100  $\mu$ l plasma samples, to analyze often both PK and PD parameters.

In rats, total brains of  $\pm 1.8$  g are obtained and homogenized. Only one sample can be taken, therefore the sample size is large. There is currently no analysis available for the measurement of remoxipride in brain homogenate. Brain microdialysis studies are bound to low perfusion speed resulting in typical microdialysate sample volumes of 10–60  $\mu$ l [2,10,11].

Analytical procedures for measuring both plasma and brain homogenate samples are complicated by the presence of interfering compounds. For plasma samples, dilution and/or protein precipitation are standard methods to clean up the samples before analysis. To analyze brain homogenate samples liquid–liquid extraction is often used as a pre-treatment. The microdialysis samples are far less polluted with interfering compounds, therefore, it remains to be seen whether sample pre-treatment is a necessity.

For experiments in rats, we here propose analytical methods for the detection of low concentrations remoxipride in small sample volumes of plasma, brain homogenate, and microdialysate, using online solid phase extraction (SPE) coupled to liquid chromatography (LC) with tandem mass spectrometry (MS–MS). The analytical method should cover the PK concentration range in all tissue types in our future experiments. For the plasma analysis a simple precipitation step was needed, and for the brain homogenates a liquid–liquid extraction step was implemented. The measure-

ment of remoxipride in microdialysate could be performed without pre-treatment of the samples.

## 2. Materials and methods

To validate our method and increase the sensitivity and throughput, we tested plasma dilution and protein precipitation by acetonitrile or perchloric acid for positive contribution to the remoxipride analysis. Several SPE cartridges were tested; hysphere silica based cyanopropyl phase (CN), resin general phase (GP), and resin strong hydrophobic phase (SH) (Spark, Emmen, The Netherlands), mixed mode cationic exchange (MCX), and weak cationic exchange (WCX) cartridges (Waters, Etten-Leur, The Netherlands). The performance of these cartridges was tested alone as well in combination with micro-column LC. Remoxipride was injected at the SPE column under acidic- and alkaline conditions. The effect of the addition of trifluoro acetic acid was investigated as well as different mobile phase ratios, to increase peak performance. The final method is presented hereunder, together with an illustrative application of these analyses after remoxipride administration in an individual rat. Because of its structural resemblance and previous use as internal standard in remoxipride measurements in plasma [12], we used raclopride as internal standard.

### 2.1. Chemical and reagents

For all procedures Purified Millipore water (MQ, 18.2 M $\Omega$  cm) from a Milli-Q<sup>®</sup> PF Plus system was used (Millipore B.V., Amsterdam, The Netherlands). Remoxipride ((S)-3-bromo-N-[1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenzamide, 371.27 g/mol, pK<sub>a</sub> 8.9 [13], was obtained from TOCRIS, Bristol, United Kingdom. The internal standard raclopride (IS, 3,5-dichloro-N-[(2S)-1-ethyl-2-pyrrolidinyl)methyl]-2-hydroxy-6-methoxybenzamide, 347.24 g/mol,  $\log K_{\text{a}}^{\text{basic}}$  9.5,  $\log K_{\text{a}}^{\text{acidic}}$  6.11 [14]), and L-cysteine were obtained from Sigma, Zwijndrecht, The Netherlands. Acetonitrile, acetic acid (both ULC/MS grade), trifluoro acetic acid (TFA, ULC/MS grade), ammonium acetate and t-butyl-methyl-ether (HPLC grade) were obtained from Biosolve B.V., Valkenswaard, The Netherlands. Ammonium hydroxide (25%), ammonium acetate (99.1%), sodium carbonate (99.9%), potassium iodide (99.9%), ethylenediaminetetraacetic acid (EDTA), perchloric acid, and L-(+)-ascorbic acid were obtained from Baker, Deventer, The Netherlands. All pH measurements were performed using a Schott CG 820 pH meter (Schott-Geräte, Germany). 10 mM Sodium phosphate homogenization buffer (pH 7.4) was prepared using

di-sodium hydrogen phosphate di-hydrate (99.5%, E. Merck Nederland B.V., Amsterdam, The Netherlands) and sodium di-hydrogen phosphate monohydrate (99%, Sigma–Aldrich, Zwijndrecht, The Netherlands). Anti-oxidant (0.1 M acetic acid, 3.3 mM L-cysteine, 0.27 M EDTA, 0.0125 mM L-(+)-ascorbic acid; S. Sarre, personal communications) and microdialysis perfusion fluid (PF [15]) was prepared, filtered, stored in glass vials ( $-20^{\circ}\text{C}$ ), and sonified before use.

## 2.2. Samples

Blank plasma-, whole brain-, and brain microdialysis samples were obtained from Male Wistar WU rats ( $245 \pm 18$  g, Charles River, The Netherlands). All animal procedures were performed in accordance with Dutch laws on animal experimentation. The study protocol was approved by the Animal Ethics Committee of Leiden University (UDEC nr. 05156). A microdialysis guide was implanted in the striatum, and 6 days later replaced by a microdialysis probe (CMA/12, 4 mm polycarbonate membrane, cut-off 20 kD, Aurora Borealis Control, Schoonebeek, The Netherlands). The next day the probe was perfused with  $2 \mu\text{l}/\text{min}$  perfusion fluid, and blank microdialysate samples were collected in a cooled fraction collector (Univentor 820 Microsampler, Antec, Netherlands) for 5 h. After administration of an overdose of Nembutal, blank blood was obtained by open heart puncture. The whole brains were harvested after transcatheterial transfusion with 50 mM phosphate buffer (pH 7.4), and the blank brains were stored at  $-80^{\circ}\text{C}$ .

### 2.2.1. Pharmacokinetic study in rats

The described analytical methods have been applied to the pharmacokinetic study of remoxipride in rats. Intranasal delivery of remoxipride was investigated to directly target the brain. Intranasal delivery is a promising alternative for oral or parenteral administration, since it avoids the high first-pass clearance of remoxipride [8,16–18]. All animal procedures were performed in accordance with Dutch laws on animal experimentation. The study protocol was approved by the Animal Ethics Committee of Leiden University (UDEC 6132). Rat experiment were performed as described by Stevens et al. [19] in seven male Wistar WU rats. In short, during anaesthetized surgery, two blood cannulas were implanted in the femoral artery and -vein for blood sampling and drug administration, respectively. Next to that, a microdialysis guide was implanted in the striatum, and 6 days later replaced by a microdialysis probe (CMA/12, 4 mm polycarbonate membrane, cut-off 20 kD). The next day the probe was perfused with  $2 \mu\text{l}/\text{min}$  perfusion fluid, and microdialysate samples were collected in the mentioned cooled fraction collector. After a 30 min blank perfusion period, remoxipride in saline (B. Braun Melsungen AG, Melsungen, Germany) was administered ( $16 \text{ mg}/\text{kg}$ ,  $t=0$ ) during a 30-min intravenous infusion, using an automated pump (Harvard apparatus 22, model 55-2222, Holliston, MA, USA). A total number of 10 blood samples per animal, of  $200 \mu\text{l}$  each, were collected from the arterial cannula in EDTA-coated vials at 10 time points during the experiment ( $t=0, 5, 10, 20, 35, 60, 90, 120, 150,$  and  $180 \text{ min}$ ). Blood was centrifuged for 15 min at 5000 rpm and the plasma was stored at  $-20^{\circ}\text{C}$ . Microdialysate samples were collected every 20 min for the first 2 h, and every 30 thereafter, until the end of the experiments. The microdialysate samples were stored at  $-80^{\circ}\text{C}$ . At  $t=240 \text{ min}$ , transcatheterial perfusion was performed with 50 mM phosphate buffer (pH 7.4), and the whole brain was removed and stored at  $-80^{\circ}\text{C}$ . The concentrations of remoxipride in the samples were measured using the described methods. Plasma- and microdialysate geometric means ( $\pm$ standard deviation (S.D.)) were plotted over time. The geometric mean of the brain homogenates were used to calculate the ratio of the concentration remoxipride in the brain versus the microdialysate concentrations.

## 2.3. Sample preparation, calibration curves and quality controls

For the plasma analysis a calibration curve of 0, 5, 10, 20, 50, 100, 200, 500, 1000, and 2000 ng/ml remoxipride M in MQ was prepared from a stock solution ( $100 \mu\text{g}$  remoxipride per ml MQ). For the quality controls (QCs), standard solutions containing remoxipride were added to 1.9 ml blank plasma (0.05:0.95, v/v), resulting in concentrations of 5, 50, 200, and 2000 ng/ml remoxipride. To  $20 \mu\text{l}$  experimental plasma samples and QCs, IS (100 ng/ml) and MQ (1:1:1, v/v/v) was added and vortexed. Standard calibration solutions were mixed with IS (100 ng/ml) and blank plasma (1:1:1, v/v/v). 6% perchloric acid ( $\text{HClO}_4$ ) was added to these mixtures (2:3, v/v) to precipitate the proteins. After brief vortexing (Vortex-Genie CM-9, Wilton en Co B.V., Etten-Leur, The Netherlands), the samples were centrifuged in eppendorf vials at 8000 rpm during 10 min (Labofuge GL centrifuge, Micro CL 21R, Thermo Fisher Scientific, Breda, The Netherlands) and  $60 \mu\text{l}$  supernatant was added to  $45 \mu\text{l}$  0.5 M  $\text{Na}_2\text{CO}_3$  and vortexed.  $10 \mu\text{l}$  of sample was injected onto the online SPE.

Brains were defrosted and homogenized with a Potter S apparatus (B. Braun, Melsungen) in phosphate buffer in a 1:5 ratio (m/v) and kept on ice. To 0.6 ml blank brain homogenate (100 mg brain) samples  $100 \mu\text{l}$  of calibration standard was added resulting in concentrations of 0, 5, 10, 20, 50, 100, 200, 400, and 500 ng remoxipride/gram brain. The quality controls (QCs) contained 5, 20, 100, and 400 ng/gram brain. To the spiked homogenates (calibration curve), QCs and samples,  $20 \mu\text{l}$  of IS (1000 ng/ml) and/or MQ was added (60:2:10, v/v/v). After vortexing, potassium iodide and 1 M  $\text{Na}_2\text{CO}_3$  were added (72:10:10, v/v/v) and subsequently vortexed. *t*-Butyl-methyl-ether was added (0.92:5, v/v), and thorough vortexing supplied transfer of remoxipride and IS from aqueous to organic phase. After centrifugation at 4000 rpm during 10 min, organic phase was transferred to clean glass tubes and evaporated in a vacuum vortex at  $40^{\circ}\text{C}$  (Labconco vortex evaporator, Beun de Ronde, Breda, The Netherlands).  $100 \mu\text{l}$  SPE solvent (Section 2.4; SPE-B) was added, mixed and sonified for 20 s. After spinning down the liquid, sample was transferred to eppendorf vials and centrifuged at 15,000 rpm.  $10 \mu\text{l}$  of supernatant was injected onto the online SPE.

For the microdialysate analysis, calibration standards were prepared in PF, resulting in concentrations of 0, 0.5, 1.0, 2.0, 5.0, 10, and 20 ng/ml remoxipride, all containing 10 ng/ml IS. The quality controls (QCs) were prepared containing 0.5, 5 and 20 ng/ml remoxipride. To  $20 \mu\text{l}$  calibration standards, QCs, or microdialysate samples,  $5 \mu\text{l}$  anti-oxidant was added and vortexed prior to injection of  $10 \mu\text{l}$  into the LC system. Anti-oxidant was used in microdialysate to prevent oxidation of molecules, other than remoxipride, that we might like to measure in the future.

## 2.4. Online SPE-LC-MS-MS system

After each injection ( $8^{\circ}\text{C}$ , Surveyor autosampler, Thermo Fisher Scientific, Breda, The Netherlands), the injection needle was washed with  $100 \mu\text{l}$  acetonitrile in MQ (1:9, v/v) and acetonitrile in MQ with acetic acid (1:3, v/v) to reduce carry-over. A Gynkotek P580 Solvent Delivery pump (Dionex Benelux B.V., Amsterdam, The Netherlands) flushed sample onto the SPE column (Hysphere Resin GP SPE in SPE cartridge holder, Spark, Emmen, The Netherlands: ambient temperature). SPE solvent A (SPE-A) consisted of acetonitrile in 10 mM ammonium acetate/ammonium hydroxide (pH 8.3, 1:4, v/v). SPE solvent B (SPE-B) consisted of 50 mM ammonium acetate/ammonium hydroxide (pH 8.3), and SPE solvent C (SPE-C) consisted of acetonitrile mixed with 16 mM acetic acid (7:3, v/v, 0.1% TFA, pH 2). The flow rate was 1 ml/min. At basic conditions, including  $t=0$ , the SPE was flushed with SPE-A solvent. After 1 min of washing, a six-port switching valve diverted the SPE to the LC

**Table 2**  
Tandem mass spectrometer settings.

	20 $\mu$ l plasma or 0.6 ml brain homogenate		20 $\mu$ l microdialysate	
	REM	IS	REM	IS
Measure window (min)	0–7	7–13	0–12	12–25
Desolvation gas (psi)	27	27	25	10
Ionization voltage (kV)	3.5	3.5	3	3.5
Fragments ( <i>m/z</i> )	112	112	112	112
	228	129	228	129
	242	219	242	204

REM; remoxipride, IS; internal standard.

system. At 5 min the SPE was switched back to the SPE pump, and flushed with SPE-C solvent C, SPE-A, and SPE-B for 3, 3, and 2 min, respectively, to precondition the column for a next injection. The SPE was used only during one LC-sequence with a maximum of about 90 injections, finalizing with QCs to verify quality.

After switching to the LC system in back flush mode, the MS pump (Surveyor MS pump, Thermo Fischer Scientific, 100  $\mu$ l/min) was used to separate the analytes on an Alltima HP C18 HPLC column (ambient temperature, 150 mm  $\times$  1.0 mm, 5  $\mu$ m, Alltech Applied Science, Breda, The Netherlands). The mobile phases (MP) consisted of acetonitrile, 10 mM acetic acid/ammonium acetate at pH 3.7, and 0.05% TFA. The latter was added to enhance peak shape and resolution. For the plasma- and brain analysis the ratio for MP-1 was 1:3 (v/v) and for MP-2 the ratio was 2:3 (v/v). A linear gradient (0–6 min, MP-1–MP-2) was applied to elute remoxipride and IS. At 10 min the LC system was reset to MP-1. The microdialysate samples were directly injected into the LC system using a mixture of MP-A and MP-B (6:4, v/v). Since no SPE was used, the flow was diverted to waste at the onset of the elution, and after 2 min the switching valve directed the flow to the MS–MS.

The Finnigan TSQ Quantum Ultra Mass Spectrometer System (Thermo Fischer Scientific) was tuned by infusing standard solutions of remoxipride or IS with the aid of a T-piece in the LC-eluent. Since remoxipride and the IS are charged, electro spray-ionization was preferred above atmospheric pressure chemical ionization, and nitrogen was used as the desolvation gas. After collision-induced dissociation by argon gas (0.8 psi), the total ion current (TIC) was measured using the fragmented ions of remoxipride (MH<sup>+</sup> = 371) and raclopride (MH<sup>+</sup> = 347). Data acquisition was performed using the software package LC-Quan provided by Thermo Scientific. For all three analysis a separate tuning of the mass spectrometer was performed.

After analysis, linear regression was used to determine the slope, intercept and correlation coefficient ( $R^2$ ) of the relation between the peak-area ratio and the drug concentration in the calibration standards data, and accepted when  $R^2 > 0.98$ . For the calibration curves weighting factors of 1, 1/Y and 1/Y<sup>2</sup> were compared.

### 2.5. Extraction yield, LLOD, LLOQ, accuracy, precision, inter- and intra-day variability

Peak-area ratios of remoxipride over IS were calculated, and remoxipride concentrations were corrected for the dilution with IS and anti-oxidant. The extraction yield was calculated by dividing the peak area's of remoxipride either before and after LLE or LC with and without SPE. The lower limit of detection (LLOD) was defined as the lowest concentration measurable by a signal–noise ratio (S/N) of 3, lower limit of quantification (LLOQ) as the lowest concentration measurable by a S/N of 10. Intra-day, inter-day variability, and accuracy for the analysis were determined by measuring replicates of the QCs. Precision was calculated as the relative standard deviation (RSD) for both intra-day and inter-day variability, and accuracy as the degree of closeness of the determined value to the

true value. Acceptable precision was defined by a RSD <15% for the standards, and <20% at LLOQ. Accuracy was allowed to deviate <15% for the standards, and <20% at LLOQ compared to the nominal values. Extraction yield, LLOD, LLOQ, accuracy, precision, inter- and intra-day variability methods and acceptance ranges are based on guidelines distilled from the Third Bioanalytical Workshop of the American Association of Pharmaceutical Scientists and Food and Drug Administration in 2006 [20].

## 3. Results and discussion


### 3.1. Method development and optimization SPE-LC–MS–MS

Online SPE was used for rat plasma and brain homogenate samples in order to provide an adequate sample clean up. As cleaning and preconditioning the SPE could be performed during elution of remoxipride and IS at the LC column, time loss due to the cleansing step was reduced.

Several SPE cartridges were tested for the optimal adsorption and elution properties. Hysphere CN was suitable for remoxipride adsorption and elution, but the internal standard Raclopride already eluted during the washing phase. On the WCX phase, remoxipride behaved as a neutral and already eluted at 100% methanol, so no proper washing could take place. The Waters MCX showed bad resolution for remoxipride, so this method was abandoned. When using the Hysphere Resin SH material, the IS behaved differently from remoxipride and showed a poor peak shape. The Hysphere Resin GP SPE gave adequate separation, retention and peak shape for both remoxipride and IS. As we wanted to use material with another separation mechanism for the SPE as for the LC, this phase was chosen. Stability of this type of material over a wide range of pH (0–14) was favourable for our application. Both remoxipride and IS are trapped on the SPE at pH 8.3 and released when the SPE is switched to the LC system that is flushing MP at pH 3.7. To optimize the peak shape, several mobile phases (MPs) were tested by varying acetonitrile content, buffer composition and pH. This resulted in the MPs as described in Section 2.4. In the plasma- and brain analysis the addition of TFA (0.05%) enhanced the peak shape of both remoxipride and IS. After tuning, using a syringe at 5  $\mu$ l/min and LC flow of 100  $\mu$ l/min, the main fragments of remoxipride and IS were identified (Table 2). For the plasma analysis the retention times of remoxipride and IS were 5.0 and 8.7 min, respectively, for the brain analysis 5.1 and 8.7 min, respectively, and for the microdialysate analysis the retention times were 4.8 and 20.7 min, respectively (Fig. 1).

### 3.2. Method validation

Table 2 provides an overview of the MS settings regarding measure window, desolvation gas pressure, ionization voltage, and measured fragment sizes derived from the total ion currents, for the plasma, brain microdialysate, and brain homogenate analysis. Specific information for the different types of samples is described




**Fig. 1.** Relative abundances of remoxipride (REM) and raclopride (IS) in different matrices. (A) Chromatogram of plasma spiked with 20 ng/ml remoxipride, (B) 2 ng/ml remoxipride in microdialysate and (C) 20 ng/ml remoxipride in brain homogenate.

**Table 3**  
Validation results of remoxipride analysis.

Plasma ( <i>n</i> = 5 over 5 consecutive days)				
LLOD (ng/ml)		0.15		
LLOQ (ng/ml)		0.5		
REM extraction yield (%)		76		
Added (ng/ml)	Mean (ng/ml)	RSD (%)		Accuracy (%)
		Inter-day	Intra-day	
5	5.1	18.1	11.8	100.6
50	48.3	4.9	3.6	108.6
200	192.5	14.7	2.1	109.8
200	195.9	11.4	1.8	97.2
2000	2091.0	5.0	2.9	102.1
Brain homogenate ( <i>n</i> = 5 over 7 consecutive days)				
LLOD (ng/ml)		0.53		
LLOQ (ng/ml)		1.8		
REM extraction yield (% ± S.D.)		45 ± 2.3		
Added (ng/ml)	Mean (ng/ml)	RSD (%)		Accuracy (%)
		Inter-day	Intra-day	
5	5.0	11.0	4.0	100.3
20	18.7	6.8	2.3	93.3
100	96.4	11.3	2.2	96.4
400	357.3	5.6	2.4	89.3
Microdialysate ( <i>n</i> = 6 over 4 consecutive days)				
LLOD (ng/ml)		0.08		
LLOQ (ng/ml)		0.25		
Added (ng/ml)	Mean (ng/ml)	RSD (%)		Accuracy (%)
		Inter-day	Intra-day	
0.5	0.6	9.2	4.1	117.8
5	4.7	10.1	7.5	93.5
20	20.7	11.3	7.0	103.7

LLOD, lower limit of detection; LLOQ, lower limit of quantification; REM, remoxipride; S.D., standard deviation; RSD, relative standard deviation.

below. For the plasma analysis in which 20  $\mu$ l plasma sample was used, the online SPE allowed us to only use a simple precipitation step, in contrast with the liquid–liquid extraction or post-column extraction described in literature [3–6]. Evaluation of the pre-treatment methods showed that using acetonitrile or precipitation with perchloric acid gave similar results. The results were better when compared to diluting plasma, which caused clogging of the system. Because of the extra evaporation step needed in the acetonitrile method, we proceeded with the more simple perchloric acid precipitation method. Rigid flushing of the SPE after injection, prevented non-volatile ions from entering the LC/MS/MS system. The thus developed sample preparation method caused an extraction yield of remoxipride of 76% (Table 3). This extraction yield was the product of the recovery of the pre-treatment, the SPE and the matrix effect. Three measurements of the SPE recovery revealed a mean recovery  $\pm$  standard deviation (S.D.) of  $92 \pm 2.6\%$ . The combined mean recovery of the pre-treatment and matrix effect was  $80 \pm 4.6\%$  ( $n = 17$ ). LLOD and LLOQ were 0.15 and 0.5 ng/ml, respectively. This indicates that while using a smaller sample volume a similar LLOD and LLOQ were obtained when compared to literature (Table 1). Using a weighting factor of  $1/Y^2$ , calibration was performed within two calibration ranges. Both calibration ranges were measured during the same run. The high standards caused a considerable memory effect.  $R^2$  for the concentration range 100–2000 ng/ml was acceptable:  $0.990 \pm 0.017$  ( $\pm$ S.D.). The lower concentration range gave an average  $R^2$  of  $0.966 \pm 0.017$ , which was most likely caused by the memory effect that increased the error on the lowest concentrations of the calibration curve.



The memory effect could later on be circumvented by injection of blanks after samples in the high range of the calibration curve. The memory effect also influenced the intra-day RSD for QCs in the low (5 ng/ml) concentration samples. The inter-day RSD for the other QCs ranged from 4.9 to 14.7%, with an average of 9.0%. The intra-day variability is thereby higher than described with other methods (Table 1), which should decrease by reducing the memory effect. For the intra-day RSD this range was 1.8–3.6%, with an average of 2.6 ng/ml which is low compared to literature, and the average accuracy  $\pm$ S.D. was  $103.7 \pm 5.3\%$ . Despite the memory effect, the precision, as indicated by the RSDs and accuracy, are within ranges (Table 3) which were suitable for the samples derived from our *in vivo* remoxipride experiments in rats.


For the analysis of the brain homogenate we needed a liquid–liquid extraction step (LLE) for the clean up of our samples. Adding potassium iodide resulted in a low, but reproducible extraction yield of  $45 \pm 2.3\%$  (mean  $\pm$  S.D.). The extraction yield consisted of the recovery of remoxipride during the LLE, the SPE and the matrix effect of brain homogenate extracts. The mean recovery  $\pm$ S.D. of the SPE was  $96 \pm 5.2\%$  ( $n=12$ ), and of the matrix effect  $68 \pm 11\%$  ( $n=8$ ). The recovery of the LLE could therefore be calculated to be approximately 69%. LOD and LLOQ were 0.53 and 1.8 ng/ml, respectively. The calibration curves ( $1/Y$ ) showed an average  $R^2 \pm$ S.D. of  $0.998 \pm 0.001$ . The inter-day RSD ranged from 5.6 to 11.3%, with an average of 8.7%. For the intra-day RSD this range was 2.2–4.0%, with an average of 2.7% and average accuracy  $\pm$ S.D. of  $94.8 \pm 4.7\%$ . The RSD and accuracy were within the acceptable ranges. Of the 100  $\mu$ l supernatant we needed 10  $\mu$ l for injection, so scaling down the amount of brain tissue needed for sample preparation would be feasible. Although from analytical perspective the extraction yield could be improved, for our experiments it is sufficient to draw conclusions about the amount of remoxipride in the intracellular fluid brain (Section 3.3).

For the microdialysate analysis no extraction step was needed, allowing direct injection of the 20  $\mu$ l brain microdialysate samples in the LC system, although this caused the LOD to be slightly higher than in the plasma analysis. Diverting the first 2 min to waste reduced the noise, thereby reducing the LOD and LLOQ to 0.08 and 0.25 ng/ml, respectively. The calibration curves ( $1/Y^2$ ) showed an  $R^2$  of  $0.986 \pm 0.015$ . The average intra-day and inter-day RSD were 6.2 and 10.2%, respectively. The average accuracy  $\pm$ S.D. was  $105 \pm 12.2\%$ . The RSD and accuracy were within the acceptable ranges. When previous reported analysis in cerebrospinal fluid [7] would be used, sample sizes ranging from 500 to 1500  $\mu$ l would be necessary. Our method allows 20  $\mu$ l sampling over time in an individual animal using microdialysis techniques.

### 3.3. Pharmacokinetic study in rats

The concentration of remoxipride was successfully measured in plasma-, brain homogenate-, and brain microdialysate samples after intravenous administration of 16 mg/kg remoxipride. Fig. 2 depicts examples of real sample chromatograms in all three matrices. Fig. 3 shows the concentration–time profiles (geometric means  $\pm$ S.D.) in plasma and brain microdialysate. The lowest measured concentrations are above the LLOQ. As expected, the maximum concentration ( $C_{max}$ ) in plasma is reached at the end of the infusion; 30 min. The  $C_{max}$  of the microdialysate concentrations lies

**Fig. 2.** Relative abundances of remoxipride (REM) and raclopride (IS) in different matrices in an individual rat after administration of 16 mg/kg remoxipride at  $t=0$ . The upper panel shows the chromatogram of the sample. The lower panels show the peaks of the IS (middle panel) and remoxipride (lower panel) within that sample. (A) Chromatograms of plasma sample at  $t=40$  min, (B) chromatograms of microdialysate sample at  $t=140$ –160 min and (C) chromatograms of a brain homogenate sample at  $t=240$  min.



**Fig. 3.** Remoxipride concentrations (geometric mean  $\pm$  standard deviation) in plasma (closed symbols) and brain microdialysate (MD, open symbols) after a 30-min intranasal infusion of 16 mg/kg remoxipride at  $t=0$  in 7 Wistar rats.

between 30 and 40 min. The delay in the microdialysate time to  $C_{max}$  implies activity at the site of the blood–brain barrier (BBB). Remoxipride acts on dopaminergic neurons that are located on the cell membranes of dopaminergic neurons. When investigating the PD in terms of efficacy and safety of compounds, understanding of the time to onset of action is vital. Interaction with the BBB has, in the case of remoxipride, evidently an effect on the time to onset of action. Although from a preclinical perspective, these results endorse the assumption that full understanding of the distribution of compound to the site of action is essential for dose-finding studies.

Moreover, the geometric mean ( $\pm$ S.D.) of the concentration in brain homogenate at  $t=240$  min was found to be  $1096 \pm 153.3$  ng/ml, with corresponding microdialysate concentration of  $8.77 \pm 1.46$  ng/ml in the microdialysate. The ratio that is present in the brain normalized by the microdialysate concentrations is therefore 125. Since this is larger than one, it is proven that a significant portion of bound remoxipride is still present in the brain, thereby increasing the complexity of the PK of remoxipride in a rat.

A single dose study does not provide sufficient information on the distribution over the BBB. To fully understand the mechanistic interpretation of the brain distribution, these studies must first be expanded with several other dosages. Secondly, after expansion, population approach non-linear mixed effect modeling should be performed to fully comprehend the PK of remoxipride in a mechanistic way. Full understanding of the PK then allows building of a mechanism-based PK–PD model of remoxipride in rat. The small sample volumes used in the analytical methods described in this article allow, for the first time, in-depth analysis of the PK of remoxipride over time in small laboratory animals.

#### 4. Conclusions

We have successfully developed online SPE–LC–MS–MS methods for the rapid analysis of remoxipride in plasma, brain microdialysates and brain homogenate.

A simple protein precipitation proved to be sufficient as plasma sample (20  $\mu$ l) clean up, before online SPE. One SPE cartridge could be used for about ninety injections, with a high extraction yield. For the measurement of remoxipride in rat brain homogenate (0.6 ml), an additional LLE was performed before online SPE. This is the first report for analyzing remoxipride in whole brain samples and although the extraction yield is relatively low, it is feasible for our *in vivo* experiments. For brain microdialysate samples (20  $\mu$ l), no pre-treatment was needed and the samples were directly injected in the LC system.

For all three sample types a good precision and accuracy of the remoxipride analysis was obtained. The LLODs are appropriate for the use in preclinical experiments. When compared to previous reports, we accomplished the analysis of remoxipride in small sample volumes, to allow collection of concentration data suitable for mechanistic pharmacological studies on remoxipride in small laboratory animals.

#### Acknowledgements

This work was supported by the Leiden/Amsterdam Center for Drug Research (Leiden, The Netherlands) and Pfizer Global Research and Development (Sandwich, England). We thank Pfizer Global Research and Development also for their financial support.

#### References

- [1] M. Hammarlund-Udenaes, L.K. Paalzow, E.C. de Lange, *Pharm. Res.* 14 (1997) 128.
- [2] R. Nadal, *CNS Drug Rev.* 7 (2001) 265.
- [3] C. de Ruiter, U.A.T. Brinkman, R.W. Frei, J. *Liquid Chromatogr. Relat. Technol.* 10 (1987) 1903.
- [4] L.B. Nilsson, *J. Chromatogr.* 526 (1990) 139.
- [5] R.H. Chiou, M.W. Lo, *J. Chromatogr.* 581 (1992) 300.
- [6] M.E. DePuy, J.L. Demetriades, D.G. Musson, J.D. Rogers, *J. Chromatogr. B: Biomed. Sci. Appl.* 700 (1997) 165.
- [7] D.C. Main, A.E. Waterman, I.C. Kilpatrick, *J. Vet. Pharmacol. Ther.* 19 (1996) 402.
- [8] M. Widman, L.B. Nilsson, B. Bryske, J. Lundstrom, *Arzneimittelforschung* 43 (1993) 287.
- [9] L.F.M. van Zutphen, V. Baumans, A.C. Beynen, *Principles of Laboratory Animal Science*, revised version, Elsevier, 2001.
- [10] C.S. Chaurasia, M. Muller, E.D. Bashaw, E. Benfeldt, J. Bolinder, R. Bullock, P.M. Bungay, E.C.M. DeLange, H. Derendorf, W.F. Elmquist, M. Hammarlund-Udenaes, C. Joukhadar, D.L. Kellogg Jr., C.E. Lunte, C.H. Nordstrom, H. Rollema, R.J. Sawchuk, B.W.Y. Cheung, V.P. Shah, L. Stahle, U. Ungerstedt, D.F. Welty, H. Yeo, *J. Clin. Pharmacol.* 47 (2007) 589.
- [11] E.C. de Lange, M. Danhof, *Clin. Pharmacokinet.* 41 (2002) 691.
- [12] S.O. Ogren, J. Lundstrom, L.B. Nilsson, *J. Neural Transm. Gen. Sect.* 94 (1993) 199.
- [13] S. Budavari, M.J. O'Neil, A. Smith, P.A. Heckelman, J.F. Kinneary, *The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals*, Merck & Co., Inc., Whitehouse Station, NJ, USA, 1996.
- [14] G. Bouchard, A. Pagliara, P.A. Carrupt, B. Testa, V. Gobry, H.H. Girault, *Pharm. Res.* 19 (2002) 1150.
- [15] B. Moghaddam, B.S. Bunney, *J. Neurochem.* 53 (1989) 652.
- [16] American Academy of Pediatrics: Committee on Drugs, *Pediatrics*, 100 (1997) 143.
- [17] C.L. Graff, G.M. Pollack, *J. Pharm. Sci.* 94 (2005) 1187.
- [18] B. Jansson, E. Bjork, *J. Drug Target.* 10 (2002) 379.
- [19] J. Stevens, E. Suidgeest, P.H. van der Graaf, M. Danhof, E.C. de Lange, *Pharm. Res.* 26 (2009) 1911.
- [20] C. Viswanathan, S. Bansal, B. Booth, A. DeStefano, M. Rose, J. Sailstad, V. Shah, J. Skelly, P. Swann, R. Weiner, *Pharm. Res.* 24 (2007) 1962.